<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Sweet syndrome (acute febrile neutrophilic dermatosis): Management and prognosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Sweet syndrome (acute febrile neutrophilic dermatosis): Management and prognosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Sweet syndrome (acute febrile neutrophilic dermatosis): Management and prognosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph F Merola, MD, MMSc, FAAD, FACR
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey Callen, MD, FACP, FAAD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 15, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H20434724">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sweet syndrome (acute febrile neutrophilic dermatosis) is a neutrophilic dermatosis characterized by the abrupt appearance of edematous and erythematous papules, plaques, or nodules on the skin. Fever, leukocytosis, and internal organ involvement can also occur. Sweet syndrome has been associated with infection, malignancy, pregnancy, and drug exposure. (See
         <a class="medical medical_review" href="/z/d/html/13784.html" rel="external">
          "Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Systemic glucocorticoid therapy is a first-line treatment for Sweet syndrome, and usually results in dramatic clinical improvement.
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          Colchicine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         , and potassium iodide are additional effective therapies.
        </p>
        <p>
         The management and prognosis of Sweet syndrome will be discussed here. Information on the clinical features and diagnosis of Sweet syndrome and an overview of other neutrophilic dermatoses are available separately. (See
         <a class="medical medical_review" href="/z/d/html/13784.html" rel="external">
          "Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5571.html" rel="external">
          "Neutrophilic dermatoses"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20433520">
         <span class="h1">
          APPROACH TO TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although a wide variety of therapeutic interventions have been utilized for Sweet syndrome, there is a paucity of high-quality data on the treatment options. Support for the use of therapies for Sweet syndrome is primarily based on case series and individual reports of clinical experience. Systemic therapies, particularly systemic glucocorticoids, are the mainstays of treatment [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
         Although spontaneous resolution after weeks to months occurs in an unknown proportion of patients with classical Sweet syndrome, the prominent symptoms and the unpredictable disease course lead us to initiate treatment in most patients. In addition, although our experience indicates that drug-induced Sweet syndrome can improve within several weeks after withdrawal of an offending medication, we have found pharmacologic therapy useful for accelerating clinical improvement in these patients [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         While malignancy-associated Sweet syndrome has resolved following treatment of an underlying cancer [
         <a href="#rid5">
          5
         </a>
         ], the frequency with which this occurs is unknown. Thus, we typically proceed with the treatment of Sweet syndrome in patients with malignancy-associated disease.
        </p>
        <p>
         Sweet syndrome can be managed on an outpatient basis. However, because the signs and symptoms of Sweet syndrome can closely resemble serious infection, patients are often hospitalized for evaluation prior to diagnosis. Outpatient management is appropriate once the diagnosis of Sweet syndrome has been made, provided internal organ involvement that requires inpatient management is not present. (See
         <a class="medical medical_review" href="/z/d/html/13784.html" rel="external">
          "Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis", section on 'Extracutaneous disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20433527">
         <span class="h1">
          FIRST-LINE THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Corticosteroid therapy is considered first-line treatment for Sweet syndrome on the basis of clinical experience that indicates a consistent and rapid response of Sweet syndrome to this intervention. Most patients require systemic therapy to achieve disease control. However, patients who present with a few, localized skin lesions (eg, less than 5 percent body surface area) and without systemic symptoms may respond well to local corticosteroid therapy.
        </p>
        <p>
         Local therapy may also be used as an adjunct to systemic glucocorticoids or other systemic agents in patients with widespread cutaneous lesions. This is often done in an attempt to reduce dependence on systemic drugs and accelerate lesion healing. The efficacy of such combination therapy has not been formally studied. Our experience suggests that combination therapy is useful.
        </p>
        <p class="headingAnchor" id="H20433534">
         <span class="h2">
          Systemic glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         The rapid and dramatic response of Sweet syndrome to systemic glucocorticoids documented in multiple case reports and case series supports their status as the treatment of choice for Sweet syndrome [
         <a href="#rid2">
          2,4,6-9
         </a>
         ]. The high likelihood of treatment success is reflected in the inclusion of the response to systemic glucocorticoids in the diagnostic criteria  (
         <a class="graphic graphic_table graphicRef85940" href="/z/d/graphic/85940.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/13784.html" rel="external">
          "Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis", section on 'Diagnostic criteria'
         </a>
         ). Systemic glucocorticoids are effective for both the cutaneous and extracutaneous manifestations of Sweet syndrome.
        </p>
        <p>
         In adults, we typically begin treatment with oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         at a dose of 0.5 to 1 mg/kg per day. Symptoms often begin to improve within 48 hours and skin lesions usually resolve within one to two weeks [
         <a href="#rid4">
          4,7
         </a>
         ]. Once disease control is attained, we attempt to taper and discontinue prednisone over the course of four to six weeks [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         In some patients, disease recurs when the dose of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         is reduced, thereby inhibiting the tapering and cessation of therapy. Prednisone at the lowest effective dose (often around 10 mg per day; typical range 5 to 20 mg per day) may be continued for an additional two to three months in these patients. Treatment with an alternative systemic first-line agent can also be initiated as a glucocorticoid-sparing agent. (See
         <a class="local">
          'Alternative first-line therapies'
         </a>
         below.)
        </p>
        <p>
         Systemic glucocorticoid therapy, though usually highly effective, is associated with a risk for multiple adverse effects. The risks of systemic glucocorticoid therapy are discussed in greater detail separately. In patients who receive long-term systemic glucocorticoids, measures to protect against osteoporosis are indicated. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20433541">
         <span class="h2">
          Topical and intralesional corticosteroids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Case reports and retrospective studies support the efficacy of local therapy alone in some patients with limited disease [
         <a href="#rid4">
          4,6,10
         </a>
         ]. High potency topical corticosteroids (eg,
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         0.05% ointment) and intralesional corticosteroid injections are utilized  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid6">
          6,10
         </a>
         ]. The comparative efficacy of topical and intralesional administration has not been evaluated. In our experience, intralesional therapy has been useful for thick plaques on the trunk or extremity that do not completely respond to topical therapy.
        </p>
        <p>
         Topical corticosteroids are usually applied twice daily to the affected area for two to three weeks. The use of occlusion may accelerate the response to therapy.
        </p>
        <p>
         For intralesional injection, we utilize
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          triamcinolone
         </a>
         acetonide in a concentration between 3 and 10 mg/mL. A dose close to the lower end of this range is preferred for thin plaques or for plaques in sites that are prone to corticosteroid-induced cutaneous atrophy, such as the face. We limit the total injected dose to 20 mg per treatment session. Lesions that respond partially can be retreated after two to four weeks. Patients who fail to respond sufficiently to local therapy are treated with systemic agents.
        </p>
        <p>
         Potential adverse effects of local corticosteroid therapy include cutaneous atrophy and pigmentary alteration. The adverse effects of topical and intralesional corticosteroids are reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">
          "Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5568.html" rel="external">
          "Intralesional corticosteroid injection", section on 'Adverse effects and pitfalls'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20433548">
         <span class="h2">
          Alternative first-line therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          Colchicine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         , and potassium iodide are less frequently utilized for Sweet syndrome than systemic glucocorticoids. These agents are used as first-line therapies when avoidance of systemic glucocorticoid therapy is preferred due to patient comorbidities or other factors. As noted above, they can also be used as glucocorticoid-sparing agents. We typically utilize colchicine or dapsone first due to the availability and generally favorable tolerability of these agents. (See
         <a class="local">
          'Systemic glucocorticoids'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H20433555">
         <span class="h3">
          Colchicine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Case reports and retrospective studies support the use of
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         in Sweet syndrome [
         <a href="#rid11">
          11-14
         </a>
         ]. Similar to systemic glucocorticoids and potassium iodide, the response to treatment is rapid. In a retrospective study of 20 adults with Sweet syndrome who were treated with colchicine (1 to 1.5 mg per day) for a mean of 15 days (range 10 to 21 days), 18 patients responded to colchicine therapy [
         <a href="#rid13">
          13
         </a>
         ]. Fever resolved within 24 to 72 hours, arthralgias disappeared within two to four days, and cutaneous lesions improved within two to five days. None of the 16 responders who were available for follow-up (range 2 to 10 years post-treatment) reported relapses after the discontinuation of therapy. Of note, patients with malignancy-associated Sweet syndrome were not included in this study, and relapses within 10 years after colchicine therapy were reported in another retrospective study [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         In the United States,
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         is available in 0.6 mg capsules or tablets. Patients are generally treated with a total of 1.2 to 1.8 mg of colchicine per day, which can be divided into one to three doses. In locations where colchicine is available in 0.5 mg pills, a total dose of 1 or 1.5 mg per day is sufficient. The drug can be discontinued upon achievement of disease control, which typically occurs within one to three weeks.
        </p>
        <p>
         Gastrointestinal toxicity (nausea, vomiting, diarrhea) are the most frequent complications of
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         therapy [
         <a href="#rid15">
          15
         </a>
         ]. More severe adverse effects, such as myopathy, neuropathy, and marrow suppression, may occur, especially in the setting of renal insufficiency or hepatic impairment [
         <a href="#rid16">
          16
         </a>
         ]. In addition, colchicine has multiple drug interactions, and concomitant therapies should be reviewed prior to treatment.
        </p>
        <p class="headingAnchor" id="H20433562">
         <span class="h3">
          Dapsone
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          Dapsone
         </a>
         is utilized in the treatment of multiple skin disorders characterized by neutrophilic infiltrates. Case reports document successful treatment of Sweet syndrome with dapsone [
         <a href="#rid4">
          4,17-20
         </a>
         ]. For adults with Sweet syndrome, dapsone is typically initiated at a low dose (eg, 25 mg per day) and increased as tolerated to reach a total daily dose of 100 to 200 mg per day. Dramatic clinical improvement has been noted within one to three weeks in treated patients [
         <a href="#rid18">
          18,20
         </a>
         ].
        </p>
        <p>
         Major side effects of
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         include hemolytic anemia, methemoglobinemia, agranulocytosis, and peripheral neuropathy. Due to the increased risk for significant drug-induced hemolytic anemia in patients with glucose-6-phosphate (G6PD) deficiency, we test for G6PD deficiency prior to the initiation of dapsone therapy. (See
         <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">
          "Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Acute hemolytic anemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20433570">
         <span class="h3">
          Potassium iodide
         </span>
         <span class="headingEndMark">
          —
         </span>
         Case series support the efficacy of potassium iodide in Sweet syndrome in adults [
         <a href="#rid6">
          6,21
         </a>
         ]. In one series, seven of eight patients treated with 300 mg of potassium iodide three times daily had a dramatic response to treatment [
         <a href="#rid21">
          21
         </a>
         ]. Tenderness, arthralgias, and high fever resolved within 48 hours, and cutaneous lesions resolved within four days. Five patients, all of whom who began potassium iodide early in the course of Sweet syndrome (within four to eight days), had no relapses after completing a two-week course of treatment. Two patients did well during treatment, but relapsed after drug discontinuation. One patient did not respond to therapy.
        </p>
        <p>
         The mechanism through which potassium iodide leads to improvement in Sweet syndrome and other neutrophilic dermatoses is not well understood. Theories include immune suppression related to potassium-iodide induced release of heparin, inhibition of neutrophil production of oxygen intermediates, or suppression of neutrophil chemotaxis [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         In adults, potassium iodide may be prescribed as pills (300 mg three times daily) or as a 1000 mg/mL saturated solution (SSKI). The treatment regimen for the solution begins with three drops with a standard medicine dropper (20 drops/mL) three times daily in water or juice to disguise the taste. The dose of potassium iodide is 50 mg per drop, resulting in a total of 450 mg administered per day. The dose is subsequently increased by one drop at each scheduled dosing up to a total of 7 to 10 drops three times daily (1050 to 1500 mg per day) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Potential adverse effects of potassium iodide include gastrointestinal distress, small bowel ulcerations (tablets), hypothyroidism, pulmonary edema, and a serious hypersensitivity reaction [
         <a href="#rid15">
          15
         </a>
         ]. Sipping the medication with a straw may help to avoid drug-related tooth discoloration.
        </p>
        <p class="headingAnchor" id="H20433577">
         <span class="h1">
          RECALCITRANT DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical experience suggests that pulse glucocorticoid therapy may be effective for severe Sweet syndrome or Sweet syndrome that fails to respond sufficiently to other therapies [
         <a href="#rid22">
          22-24
         </a>
         ]. In adults, intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         at doses of up to 500 to 1000 mg per day may be administered for three to five days. Treatment is followed by an oral glucocorticoid taper or another systemic immunosuppressive therapy [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p>
         In addition, oral retinoids (eg,
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         [
         <a href="#rid25">
          25
         </a>
         ], etretinate [
         <a href="#rid26">
          26
         </a>
         ]),
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         [
         <a href="#rid27">
          27,28
         </a>
         ],
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         [
         <a href="#rid29">
          29,30
         </a>
         ],
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         [
         <a href="#rid31">
          31
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">
          anakinra
         </a>
         [
         <a href="#rid32">
          32
         </a>
         ] have been successfully utilized for Sweet syndrome in patients who have failed to respond to standard therapies. Newer case reports have suggested benefit from
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          adalimumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">
          ustekinumab
         </a>
         , and the Janus kinase (JAK) inhibitor
         <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">
          baricitinib
         </a>
         in refractory cases [
         <a href="#rid33">
          33-37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20433584">
         <span class="h1">
          OTHER THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of additional treatments have been reported to be effective for Sweet syndrome in small numbers of patients [
         <a href="#rid4">
          4
         </a>
         ]. In an open study in which 18 adults with Sweet syndrome were treated with 150 mg per day of
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         for one week followed by 100 mg per day for two weeks if initial signs of improvement were detected, 17 of 18 patients responded well to treatment [
         <a href="#rid38">
          38
         </a>
         ]. Fever and arthralgias improved within two days and disease remissions occurred within two weeks. Relapses were not observed during the follow-up period (12 to 36 months). However, the development of Sweet syndrome during indomethacin treatment has been reported [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         Other agents that have been associated with clinical improvement in Sweet syndrome in case reports include various nonsteroidal anti-inflammatory drugs, tetracyclines,
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          clofazimine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , and other antibiotics [
         <a href="#rid4">
          4,7,22,38,39
         </a>
         ]. High-dose
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         appeared beneficial in a small, uncontrolled study.
        </p>
        <p class="headingAnchor" id="H20433591">
         <span class="h1">
          CHILDREN
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial approach to the treatment of Sweet syndrome is similar in adults and children. As in adults, Sweet syndrome in children usually responds rapidly to systemic glucocorticoid therapy. We typically begin treatment with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         at a dose of 1 mg/kg day in children; other authors have utilized initial doses of 2 mg/kg of prednisone per day [
         <a href="#rid2">
          2,40
         </a>
         ]. Experience with other therapies for Sweet syndrome is limited, and data on the efficacy and optimal dosing of other agents considered useful for Sweet syndrome are lacking in children.
        </p>
        <p class="headingAnchor" id="H20433598">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Without treatment, the duration of Sweet syndrome is unpredictable; spontaneous resolution may occur after weeks to months [
         <a href="#rid41">
          41
         </a>
         ]. The proportion of patients who achieve spontaneous resolution is unknown since no placebo controlled randomized trials have been performed in Sweet syndrome, and most patients receive treatment. In one retrospective study of 80 patients from six different dermatology departments in the United Kingdom, spontaneous resolution was documented in 16 patients who did not happen to receive treatment [
         <a href="#rid10">
          10
         </a>
         ]. Another retrospective study of 48 adults with Sweet syndrome documented resolution without therapeutic intervention in three patients [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         The cutaneous lesions of Sweet syndrome usually heal without scarring [
         <a href="#rid22">
          22,41
         </a>
         ] provided ulceration has not occurred. However, postinflammatory hyperpigmentation that takes months to resolve may occur at the sites of recently healed lesions. While major involvement of internal organs can occur in Sweet syndrome, death from Sweet syndrome is rare.
        </p>
        <p>
         Relapse may occur after the tapering or discontinuation of systemic glucocorticoids or other therapies and may be more likely to occur in patients with malignancy-associated disease  (
         <a class="graphic graphic_table graphicRef85941" href="/z/d/graphic/85941.html" rel="external">
          table 3
         </a>
         ). Recurrences of Sweet syndrome occur in approximately 30 percent of patients with classical Sweet syndrome [
         <a href="#rid22">
          22
         </a>
         ]. The rate of recurrence may be as high as 69 percent in the setting of underlying hematologic malignancy [
         <a href="#rid43">
          43,44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20433605">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease overview
         </strong>
         – Sweet syndrome (acute febrile neutrophilic dermatosis) is an inflammatory disorder characterized by the presence of inflammatory papules, plaques, or nodules on the skin, systemic symptoms, and neutrophilic infiltration of the skin. Sweet syndrome is often divided into three categories based on etiology: classical Sweet syndrome, malignancy-associated Sweet syndrome, and drug-induced Sweet syndrome  (
         <a class="graphic graphic_table graphicRef85941" href="/z/d/graphic/85941.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/13784.html" rel="external">
          "Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis", section on 'Classification'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial treatment for adults
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mild disease without significant systemic symptoms
         </strong>
         – For adults who present with mild Sweet syndrome (eg, less than 5 percent body surface area involvement and absence of significant systemic symptoms), we suggest the use of high potency topical corticosteroids or intralesional corticosteroid injections as initial treatment due to the relative safety of these interventions (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Extensive disease and/or systemic symptoms
         </strong>
         – For adults with more extensive involvement and/or systemic symptoms, we suggest treatment with systemic glucocorticoid therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'First-line therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For adults with Sweet syndrome who cannot be treated with systemic glucocorticoids due to comorbidities or other factors, we suggest treatment with
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         or
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Potassium iodide is also effective. (See
         <a class="local">
          'Alternative first-line therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial treatment for children
         </strong>
         – For children with Sweet syndrome, we suggest systemic glucocorticoid therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Data on the use of alternative therapies in children are limited. (See
         <a class="local">
          'Children'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Refractory disease
         </strong>
         – Pulsed intravenous glucocorticoids and other immunomodulatory therapies may be effective for patients with refractory disease. (See
         <a class="local">
          'Recalcitrant disease'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Halpern J, Salim A. Pediatric sweet syndrome: case report and literature review. Pediatr Dermatol 2009; 26:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uihlein LC, Brandling-Bennett HA, Lio PA, Liang MG. Sweet syndrome in children. Pediatr Dermatol 2012; 29:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rochet NM, Chavan RN, Cappel MA, et al. Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients. J Am Acad Dermatol 2013; 69:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen PR, Kurzrock R. Sweet's syndrome: a review of current treatment options. Am J Clin Dermatol 2002; 3:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Connor Reina C, Garcia Iriarte MT, Rodriguez Diaz A, et al. Tonsil cancer and Sweet's syndrome. Otolaryngol Head Neck Surg 1998; 119:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen PR, Holder WR, Tucker SB, et al. Sweet syndrome in patients with solid tumors. Cancer 1993; 72:2723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol 1994; 31:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahajan VK, Sharma NL, Sharma RC. Sweet's syndrome from an Indian perspective: a report of four cases and review of the literature. Int J Dermatol 2006; 45:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zamanian A, Ameri A. Acute febrile neutrophilic dermatosis (Sweet's syndrome): a study of 15 cases in Iran. Int J Dermatol 2007; 46:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourke JF, Keohane S, Long CC, et al. Sweet's syndrome and malignancy in the U.K. Br J Dermatol 1997; 137:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suehisa S, Tagami H. Treatment of acute febrile neutrophilic dermatosis (Sweet's syndrome) with colchicine. Br J Dermatol 1981; 105:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suehisa S, Tagami H, Inoue F, et al. Colchicine in the treatment of acute febrile neutrophilic dermatosis (Sweet's syndrome). Br J Dermatol 1983; 108:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maillard H, Leclech C, Peria P, et al. Colchicine for Sweet's syndrome. A study of 20 cases. Br J Dermatol 1999; 140:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amouri M, Masmoudi A, Ammar M, et al. Sweet's syndrome: a retrospective study of 90 cases from a tertiary care center. Int J Dermatol 2016; 55:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanchez MR. Miscellaneous treatments: thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine. Clin Dermatol 2000; 18:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan TP, King LE Jr, Boyd AS. Colchicine in dermatology. J Am Acad Dermatol 1998; 39:993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiff BL, Kern AB, Bercovitch L. Sweet's syndrome: report of two atypical cases. Postgrad Med 1982; 71:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           el Sherif AI, Bharija SC, Belhaj MS, Singh G. Dapsone in Sweet syndrome. Int J Dermatol 1990; 29:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sitjas D, Puig L, Cuatrecasas M, De Moragas JM. Acute febrile neutrophilic dermatosis (Sweet's syndrome). Int J Dermatol 1993; 32:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aram H. Acute febrile neutrophilic dermatosis (Sweet's syndrome). Response to dapsone. Arch Dermatol 1984; 120:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horio T, Danno K, Okamoto H, et al. Potassium iodide in erythema nodosum and other erythematous dermatoses. J Am Acad Dermatol 1983; 9:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen PR. Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2007; 2:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Case JD, Smith SZ, Callen JP. The use of pulse methylprednisolone and chlorambucil in the treatment of Sweet's syndrome. Cutis 1989; 44:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khatri ML, Taha M. Sweet's syndrome associated with myelodysplastic syndrome presenting as periorbital cellulitis. Int J Dermatol 2007; 46:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rujiwetpongstorn R, Chuamanochan M, Tovanabutra N, et al. Efficacy of acitretin in the treatment of reactive neutrophilic dermatoses in adult-onset immunodeficiency due to interferon-gamma autoantibody. J Dermatol 2020; 47:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altomare G, Capella GL, Frigerio E. Sweet's syndrome in a patient with idiopathic myelofibrosis and thymoma-myasthenia gravis-immunodeficiency complex: efficacy of treatment with etretinate. Haematologica 1996; 81:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von den Driesch P, Steffan C, Zöbe A, Hornstein OP. Sweet's syndrome--therapy with cyclosporin. Clin Exp Dermatol 1994; 19:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourke JF, Berth-Jones J, Graham-Brown RA. Sweet's syndrome responding to cyclosporin. Br J Dermatol 1992; 127:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walling HW, Snipes CJ, Gerami P, Piette WW. The relationship between neutrophilic dermatosis of the dorsal hands and sweet syndrome: report of 9 cases and comparison to atypical pyoderma gangrenosum. Arch Dermatol 2006; 142:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hrin ML, Williams J, Bowers NL, et al. Evaluation of Methotrexate in the Management of Sweet Syndrome. J Cutan Med Surg 2022; 26:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Browning CE, Dixon JE, Malone JC, Callen JP. Thalidomide in the treatment of recalcitrant Sweet's syndrome associated with myelodysplasia. J Am Acad Dermatol 2005; 53:S135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kluger N, Gil-Bistes D, Guillot B, Bessis D. Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret®) in a case of refractory Sweet's syndrome. Dermatology 2011; 222:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seminario-Vidal L, Guerrero C, Sami N. Refractory Sweet's syndrome successfully treated with rituximab. JAAD Case Rep 2015; 1:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hashemi SM, Fazeli SA, Vahedi A, Golabchifard R. Rituximab for refractory subcutaneous Sweet's syndrome in chronic lymphocytic leukemia: A case report. Mol Clin Oncol 2016; 4:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal A, Barrow W, Selim MA, Nicholas MW. Refractory Subcutaneous Sweet Syndrome Treated With Adalimumab. JAMA Dermatol 2016; 152:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joshi TP, Friske SK, Hsiou DA, Duvic M. New Practical Aspects of Sweet Syndrome. Am J Clin Dermatol 2022; 23:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nousari Y, Wu BC, Valenzuela G. Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome. Clin Exp Dermatol 2021; 46:1330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeanfils S, Joly P, Young P, et al. Indomethacin treatment of eighteen patients with Sweet's syndrome. J Am Acad Dermatol 1997; 36:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saxe N, Gordon W. Acute febrile neutrophilic dermatosis (Sweet's syndrome). Four case reports. S Afr Med J 1978; 53:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim MJ, Choe YH. EPONYM. Sweet syndrome. Eur J Pediatr 2010; 169:1439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SWEET RD. AN ACUTE FEBRILE NEUTROPHILIC DERMATOSIS. Br J Dermatol 1964; 76:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fett DL, Gibson LE, Su WP. Sweet's syndrome: systemic signs and symptoms and associated disorders. Mayo Clin Proc 1995; 70:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wawrzycki B, Chodorowska G, Pietrzak A, et al. Recurrent skin eruption in patient with chronic lymphocytic leukemia and lymphocytic infiltrates of the dermis resembling Sweet's syndrome. G Ital Dermatol Venereol 2011; 146:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi HJ, Chang SE, Lee MW, et al. A case of recurrent Sweet's syndrome in an 80-year-old man: a clue to an underlying malignancy. Int J Dermatol 2006; 45:457.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 86567 Version 12.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19689524" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Pediatric sweet syndrome: case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22011318" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Sweet syndrome in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23891394" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11893223" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Sweet's syndrome: a review of current treatment options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9852556" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Tonsil cancer and Sweet's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8402496" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Sweet syndrome in patients with solid tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8089280" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Sweet's syndrome (acute febrile neutrophilic dermatosis)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16796632" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Sweet's syndrome from an Indian perspective: a report of four cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17550553" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Acute febrile neutrophilic dermatosis (Sweet's syndrome): a study of 15 cases in Iran.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9390341" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Sweet's syndrome and malignancy in the U.K.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7295564" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Treatment of acute febrile neutrophilic dermatosis (Sweet's syndrome) with colchicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6821647" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Colchicine in the treatment of acute febrile neutrophilic dermatosis (Sweet's syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10233302" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Colchicine for Sweet's syndrome. A study of 20 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26967709" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Sweet's syndrome: a retrospective study of 90 cases from a tertiary care center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10701095" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Miscellaneous treatments: thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9843014" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Colchicine in dermatology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7054779" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Sweet's syndrome: report of two atypical cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2269574" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Dapsone in Sweet syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8486457" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Acute febrile neutrophilic dermatosis (Sweet's syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6696481" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Acute febrile neutrophilic dermatosis (Sweet's syndrome). Response to dapsone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6886108" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Potassium iodide in erythema nodosum and other erythematous dermatoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17655751" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2758862" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The use of pulse methylprednisolone and chlorambucil in the treatment of Sweet's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17472681" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Sweet's syndrome associated with myelodysplastic syndrome presenting as periorbital cellulitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32207168" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Efficacy of acitretin in the treatment of reactive neutrophilic dermatoses in adult-onset immunodeficiency due to interferon-gamma autoantibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8900854" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Sweet's syndrome in a patient with idiopathic myelofibrosis and thymoma-myasthenia gravis-immunodeficiency complex: efficacy of treatment with etretinate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8033398" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Sweet's syndrome--therapy with cyclosporin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1637692" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Sweet's syndrome responding to cyclosporin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16415387" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The relationship between neutrophilic dermatosis of the dorsal hands and sweet syndrome: report of 9 cases and comparison to atypical pyoderma gangrenosum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35822306" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Evaluation of Methotrexate in the Management of Sweet Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16021163" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Thalidomide in the treatment of recalcitrant Sweet's syndrome associated with myelodysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21464561" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret®) in a case of refractory Sweet's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27051705" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Refractory Sweet's syndrome successfully treated with rituximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26998300" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Rituximab for refractory subcutaneous Sweet's syndrome in chronic lymphocytic leukemia: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27028556" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Refractory Subcutaneous Sweet Syndrome Treated With Adalimumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35157247" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : New Practical Aspects of Sweet Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33914946" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9091476" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Indomethacin treatment of eighteen patients with Sweet's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/653521" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Acute febrile neutrophilic dermatosis (Sweet's syndrome). Four case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20445990" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : EPONYM. Sweet syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14201182" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : AN ACUTE FEBRILE NEUTROPHILIC DERMATOSIS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7861810" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Sweet's syndrome: systemic signs and symptoms and associated disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22095180" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Recurrent skin eruption in patient with chronic lymphocytic leukemia and lymphocytic infiltrates of the dermis resembling Sweet's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16650178" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A case of recurrent Sweet's syndrome in an 80-year-old man: a clue to an underlying malignancy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
